Get started
Author

Loukia Georgiou Karacosta

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
2019 · Michael P. Menden, Dennis Wang, et al. · Nature Communications · 362
PDF
Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution
2019 · Loukia G. Karacosta, Benedict Anchang, et al. · Nature Communications · 218
PDF
Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells
2017 · Angela M. Gocher, Gissou Azabdaftari, et al. · Journal of Biological Chemistry · 127
A Regulatory Feedback Loop Between Ca2+/Calmodulin-dependent Protein Kinase Kinase 2 (CaMKK2) and the Androgen Receptor in Prostate Cancer Progression
2012 · Loukia G. Karacosta, Barbara A. Foster, et al. · Journal of Biological Chemistry · 75
PDF
DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity
2018 · Benedict Anchang, Kara L. Davis, et al. · Proceedings of the National Academy of Sciences · 49
PDF
Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge
2021 · Gina Bouchard, Fernando Jose Garcia-Marques, et al. · Cancer Research · 31
Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis
2017 · Swetha Tati, John C. Fisk, et al. · Neoplasia · 17
Nucleoporin 62 and Ca2+/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells
2015 · Loukia G. Karacosta, Laura A. Kuroski, et al. · The Prostate · 17
Preclinical Analysis of JAA-F11, a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging
2018 · Loukia G. Karacosta, John C. Fisk, et al. · Translational Oncology · 16
Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation
2023 · Frederick R. Adler, Alexander R.A. Anderson, et al. · Cell Systems · 14
Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry
2023 · Loukia G. Karacosta, Danny Pancirer, et al. · Scientific Reports · 11
PDF
From imaging a single cell to implementing precision medicine: an exciting new era
2021 · Loukia G. Karacosta · Emerging Topics in Life Sciences · 8
PDF
Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level
2023 · Sayantan Bhattacharyya, Shafqat F. Ehsan, et al. · Frontiers in Network Physiology · 7
PDF
YAP1 Defines an Emergent, Plastic Population of Relapsed SCLC
2026 · C. Allison Stewart, Kavya Ramkumar, et al. · Journal of Thoracic Oncology · 5
Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
2017 · Iakovos Toumazis, Murat Kurt, et al. · MDM Policy & Practice · 4
Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models
2022 · Diala Ghazal, Fatma Zalzala, et al. · Oncotarget · 3
PDF
Abstract 4997: Identifying dynamic EMT states and constructing a proteomic EMT landscape of lung cancer using single cell multidimensional analysis
2018 · Loukia G. Karacosta, Benedict Anchang, et al. · Cancer Research · 3
CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level
2025 · Mukulika Bose, Cole Ruoff, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Corrigendum to “Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis” [Neoplasia 19.9 (2017) 716-733]
2017 · Swetha Tati, John C. Fisk, et al. · Neoplasia · 2
PDF
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report
2025 · Kaiwen Wang, Ceylan Altintas Taslic, et al. · JTO Clinical and Research Reports · 1
P3.13.09 Surface Targeting Strategies to Overcome Heterogeneity Associated With Treatment Resistance in Small Cell Lung Cancer (SCLC)
2025 · A. Stewart, K. Ramkumar, et al. · Journal of Thoracic Oncology · 1
EP16.02-015 Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
2022 · L.G. Karacosta, D. Pancirer, et al. · Journal of Thoracic Oncology · 1
Multi-Omics Analysis of Fibroblasts from the Invasive Tumor Edge Reveals that Tumor-Stroma Crosstalk Induces O-glycosylation of the CDK4-pRB Axis
2021 · Gina Bouchard, Fernando Jose Garcia Marques, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract 2275: Individualized drug combination based on single-cell drug perturbations
2018 · Benedict Anchang, Kara Davis, et al. · Cancer Research · 1
DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab
2026 · Bingnan Zhang, Lingzhi Hong, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 71
Citation count: 938
H-index: 10
I10-index: 10
Year
Topic
Type